The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues...
Ausführliche Beschreibung
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Frontiers in Public Health - Frontiers Media S.A., 2013, 9(2021) |
---|---|
Übergeordnetes Werk: |
volume:9 ; year:2021 |
Links: |
---|
DOI / URN: |
10.3389/fpubh.2021.671961 |
---|
Katalog-ID: |
DOAJ062907832 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ062907832 | ||
003 | DE-627 | ||
005 | 20230502115246.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fpubh.2021.671961 |2 doi | |
035 | |a (DE-627)DOAJ062907832 | ||
035 | |a (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RA1-1270 | |
100 | 0 | |a Brian Godman |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. | ||
650 | 4 | |a Africa | |
650 | 4 | |a biosimilars | |
650 | 4 | |a cross-national study | |
650 | 4 | |a drug utilisation | |
650 | 4 | |a Europe | |
650 | 4 | |a health policy | |
653 | 0 | |a Public aspects of medicine | |
700 | 0 | |a Brian Godman |e verfasserin |4 aut | |
700 | 0 | |a Brian Godman |e verfasserin |4 aut | |
700 | 0 | |a Mainul Haque |e verfasserin |4 aut | |
700 | 0 | |a Trudy Leong |e verfasserin |4 aut | |
700 | 0 | |a Eleonora Allocati |e verfasserin |4 aut | |
700 | 0 | |a Santosh Kumar |e verfasserin |4 aut | |
700 | 0 | |a Salequl Islam |e verfasserin |4 aut | |
700 | 0 | |a Jaykaran Charan |e verfasserin |4 aut | |
700 | 0 | |a Farhana Akter |e verfasserin |4 aut | |
700 | 0 | |a Amanj Kurdi |e verfasserin |4 aut | |
700 | 0 | |a Amanj Kurdi |e verfasserin |4 aut | |
700 | 0 | |a Amanj Kurdi |e verfasserin |4 aut | |
700 | 0 | |a Carlos Vassalo |e verfasserin |4 aut | |
700 | 0 | |a Muhammed Abu Bakar |e verfasserin |4 aut | |
700 | 0 | |a Sagir Abdur Rahim |e verfasserin |4 aut | |
700 | 0 | |a Nusrat Sultana |e verfasserin |4 aut | |
700 | 0 | |a Farzana Deeba |e verfasserin |4 aut | |
700 | 0 | |a M. A. Halim Khan |e verfasserin |4 aut | |
700 | 0 | |a A. B. M. Muksudul Alam |e verfasserin |4 aut | |
700 | 0 | |a Iffat Jahan |e verfasserin |4 aut | |
700 | 0 | |a Zubair Mahmood Kamal |e verfasserin |4 aut | |
700 | 0 | |a Humaira Hasin |e verfasserin |4 aut | |
700 | 0 | |a Munzur-E-Murshid |e verfasserin |4 aut | |
700 | 0 | |a Shamsun Nahar |e verfasserin |4 aut | |
700 | 0 | |a Monami Haque |e verfasserin |4 aut | |
700 | 0 | |a Siddhartha Dutta |e verfasserin |4 aut | |
700 | 0 | |a Jha Pallavi Abhayanand |e verfasserin |4 aut | |
700 | 0 | |a Rimple Jeet Kaur |e verfasserin |4 aut | |
700 | 0 | |a Godfrey Mutashambara Rwegerera |e verfasserin |4 aut | |
700 | 0 | |a Godfrey Mutashambara Rwegerera |e verfasserin |4 aut | |
700 | 0 | |a Renata Cristina Rezende Macedo do Nascimento |e verfasserin |4 aut | |
700 | 0 | |a Isabella Piassi Dias Godói |e verfasserin |4 aut | |
700 | 0 | |a Isabella Piassi Dias Godói |e verfasserin |4 aut | |
700 | 0 | |a Mohammed Irfan |e verfasserin |4 aut | |
700 | 0 | |a Adefolarin A. Amu |e verfasserin |4 aut | |
700 | 0 | |a Patrick Matowa |e verfasserin |4 aut | |
700 | 0 | |a Joseph Acolatse |e verfasserin |4 aut | |
700 | 0 | |a Robert Incoom |e verfasserin |4 aut | |
700 | 0 | |a Israel Abebrese Sefah |e verfasserin |4 aut | |
700 | 0 | |a Israel Abebrese Sefah |e verfasserin |4 aut | |
700 | 0 | |a Jitendra Acharya |e verfasserin |4 aut | |
700 | 0 | |a Sylvia Opanga |e verfasserin |4 aut | |
700 | 0 | |a Lisper Wangeci Njeri |e verfasserin |4 aut | |
700 | 0 | |a David Kimonge |e verfasserin |4 aut | |
700 | 0 | |a Hye-Young Kwon |e verfasserin |4 aut | |
700 | 0 | |a SeungJin Bae |e verfasserin |4 aut | |
700 | 0 | |a Karen Koh Pek Khuan |e verfasserin |4 aut | |
700 | 0 | |a Abdullahi Rabiu Abubakar |e verfasserin |4 aut | |
700 | 0 | |a Ibrahim Haruna Sani |e verfasserin |4 aut | |
700 | 0 | |a Tanveer Ahmed Khan |e verfasserin |4 aut | |
700 | 0 | |a Shahzad Hussain |e verfasserin |4 aut | |
700 | 0 | |a Zikria Saleem |e verfasserin |4 aut | |
700 | 0 | |a Oliver Ombeva Malande |e verfasserin |4 aut | |
700 | 0 | |a Oliver Ombeva Malande |e verfasserin |4 aut | |
700 | 0 | |a Thereza Piloya-Were |e verfasserin |4 aut | |
700 | 0 | |a Rosana Gambogi |e verfasserin |4 aut | |
700 | 0 | |a Carla Hernandez Ortiz |e verfasserin |4 aut | |
700 | 0 | |a Luke Alutuli |e verfasserin |4 aut | |
700 | 0 | |a Aubrey Chichonyi Kalungia |e verfasserin |4 aut | |
700 | 0 | |a Iris Hoxha |e verfasserin |4 aut | |
700 | 0 | |a Vanda Marković-Peković |e verfasserin |4 aut | |
700 | 0 | |a Biljana Tubic |e verfasserin |4 aut | |
700 | 0 | |a Biljana Tubic |e verfasserin |4 aut | |
700 | 0 | |a Guenka Petrova |e verfasserin |4 aut | |
700 | 0 | |a Konstantin Tachkov |e verfasserin |4 aut | |
700 | 0 | |a Ott Laius |e verfasserin |4 aut | |
700 | 0 | |a András Harsanyi |e verfasserin |4 aut | |
700 | 0 | |a András Inotai |e verfasserin |4 aut | |
700 | 0 | |a András Inotai |e verfasserin |4 aut | |
700 | 0 | |a Arianit Jakupi |e verfasserin |4 aut | |
700 | 0 | |a Svens Henkuzens |e verfasserin |4 aut | |
700 | 0 | |a Kristina Garuoliene |e verfasserin |4 aut | |
700 | 0 | |a Jolanta Gulbinovič |e verfasserin |4 aut | |
700 | 0 | |a Magdalene Wladysiuk |e verfasserin |4 aut | |
700 | 0 | |a Magdalene Wladysiuk |e verfasserin |4 aut | |
700 | 0 | |a Jakub Rutkowski |e verfasserin |4 aut | |
700 | 0 | |a Ileana Mardare |e verfasserin |4 aut | |
700 | 0 | |a Jurij Fürst |e verfasserin |4 aut | |
700 | 0 | |a Stuart McTaggart |e verfasserin |4 aut | |
700 | 0 | |a Sean MacBride-Stewart |e verfasserin |4 aut | |
700 | 0 | |a Caridad Pontes |e verfasserin |4 aut | |
700 | 0 | |a Caridad Pontes |e verfasserin |4 aut | |
700 | 0 | |a Corinne Zara |e verfasserin |4 aut | |
700 | 0 | |a Eunice Twumwaa Tagoe |e verfasserin |4 aut | |
700 | 0 | |a Rita Banzi |e verfasserin |4 aut | |
700 | 0 | |a Janney Wale |e verfasserin |4 aut | |
700 | 0 | |a Mihajlo Jakovljevic |e verfasserin |4 aut | |
700 | 0 | |a Mihajlo Jakovljevic |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Frontiers in Public Health |d Frontiers Media S.A., 2013 |g 9(2021) |w (DE-627)742224589 |w (DE-600)2711781-9 |x 22962565 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2021 |
856 | 4 | 0 | |u https://doi.org/10.3389/fpubh.2021.671961 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad |z kostenfrei |
856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2296-2565 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 9 |j 2021 |
author_variant |
b g bg b g bg b g bg m h mh t l tl e a ea s k sk s i si j c jc f a fa a k ak a k ak a k ak c v cv m a b mab s a r sar n s ns f d fd m a h k mahk a b m m a abmma i j ij z m k zmk h h hh m e me s n sn m h mh s d sd j p a jpa r j k rjk g m r gmr g m r gmr r c r m d n rcrmdn i p d g ipdg i p d g ipdg m i mi a a a aaa p m pm j a ja r i ri i a s ias i a s ias j a ja s o so l w n lwn d k dk h y k hyk s b sb k k p k kkpk a r a ara i h s ihs t a k tak s h sh z s zs o o m oom o o m oom t p w tpw r g rg c h o cho l a la a c k ack i h ih v m p vmp b t bt b t bt g p gp k t kt o l ol a h ah a i ai a i ai a j aj s h sh k g kg j g jg m w mw m w mw j r jr i m im j f jf s m sm s m s sms c p cp c p cp c z cz e t t ett r b rb j w jw m j mj m j mj |
---|---|
matchkey_str |
article:22962565:2021----::hcretiutorgrigogcignuiaaousnldnboiiasmnarcnsaerpaadotaeiac |
hierarchy_sort_str |
2021 |
callnumber-subject-code |
RA |
publishDate |
2021 |
allfields |
10.3389/fpubh.2021.671961 doi (DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad DE-627 ger DE-627 rakwb eng RA1-1270 Brian Godman verfasserin aut The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine Brian Godman verfasserin aut Brian Godman verfasserin aut Mainul Haque verfasserin aut Trudy Leong verfasserin aut Eleonora Allocati verfasserin aut Santosh Kumar verfasserin aut Salequl Islam verfasserin aut Jaykaran Charan verfasserin aut Farhana Akter verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Carlos Vassalo verfasserin aut Muhammed Abu Bakar verfasserin aut Sagir Abdur Rahim verfasserin aut Nusrat Sultana verfasserin aut Farzana Deeba verfasserin aut M. A. Halim Khan verfasserin aut A. B. M. Muksudul Alam verfasserin aut Iffat Jahan verfasserin aut Zubair Mahmood Kamal verfasserin aut Humaira Hasin verfasserin aut Munzur-E-Murshid verfasserin aut Shamsun Nahar verfasserin aut Monami Haque verfasserin aut Siddhartha Dutta verfasserin aut Jha Pallavi Abhayanand verfasserin aut Rimple Jeet Kaur verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Renata Cristina Rezende Macedo do Nascimento verfasserin aut Isabella Piassi Dias Godói verfasserin aut Isabella Piassi Dias Godói verfasserin aut Mohammed Irfan verfasserin aut Adefolarin A. Amu verfasserin aut Patrick Matowa verfasserin aut Joseph Acolatse verfasserin aut Robert Incoom verfasserin aut Israel Abebrese Sefah verfasserin aut Israel Abebrese Sefah verfasserin aut Jitendra Acharya verfasserin aut Sylvia Opanga verfasserin aut Lisper Wangeci Njeri verfasserin aut David Kimonge verfasserin aut Hye-Young Kwon verfasserin aut SeungJin Bae verfasserin aut Karen Koh Pek Khuan verfasserin aut Abdullahi Rabiu Abubakar verfasserin aut Ibrahim Haruna Sani verfasserin aut Tanveer Ahmed Khan verfasserin aut Shahzad Hussain verfasserin aut Zikria Saleem verfasserin aut Oliver Ombeva Malande verfasserin aut Oliver Ombeva Malande verfasserin aut Thereza Piloya-Were verfasserin aut Rosana Gambogi verfasserin aut Carla Hernandez Ortiz verfasserin aut Luke Alutuli verfasserin aut Aubrey Chichonyi Kalungia verfasserin aut Iris Hoxha verfasserin aut Vanda Marković-Peković verfasserin aut Biljana Tubic verfasserin aut Biljana Tubic verfasserin aut Guenka Petrova verfasserin aut Konstantin Tachkov verfasserin aut Ott Laius verfasserin aut András Harsanyi verfasserin aut András Inotai verfasserin aut András Inotai verfasserin aut Arianit Jakupi verfasserin aut Svens Henkuzens verfasserin aut Kristina Garuoliene verfasserin aut Jolanta Gulbinovič verfasserin aut Magdalene Wladysiuk verfasserin aut Magdalene Wladysiuk verfasserin aut Jakub Rutkowski verfasserin aut Ileana Mardare verfasserin aut Jurij Fürst verfasserin aut Stuart McTaggart verfasserin aut Sean MacBride-Stewart verfasserin aut Caridad Pontes verfasserin aut Caridad Pontes verfasserin aut Corinne Zara verfasserin aut Eunice Twumwaa Tagoe verfasserin aut Rita Banzi verfasserin aut Janney Wale verfasserin aut Mihajlo Jakovljevic verfasserin aut Mihajlo Jakovljevic verfasserin aut In Frontiers in Public Health Frontiers Media S.A., 2013 9(2021) (DE-627)742224589 (DE-600)2711781-9 22962565 nnns volume:9 year:2021 https://doi.org/10.3389/fpubh.2021.671961 kostenfrei https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad kostenfrei https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full kostenfrei https://doaj.org/toc/2296-2565 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 |
spelling |
10.3389/fpubh.2021.671961 doi (DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad DE-627 ger DE-627 rakwb eng RA1-1270 Brian Godman verfasserin aut The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine Brian Godman verfasserin aut Brian Godman verfasserin aut Mainul Haque verfasserin aut Trudy Leong verfasserin aut Eleonora Allocati verfasserin aut Santosh Kumar verfasserin aut Salequl Islam verfasserin aut Jaykaran Charan verfasserin aut Farhana Akter verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Carlos Vassalo verfasserin aut Muhammed Abu Bakar verfasserin aut Sagir Abdur Rahim verfasserin aut Nusrat Sultana verfasserin aut Farzana Deeba verfasserin aut M. A. Halim Khan verfasserin aut A. B. M. Muksudul Alam verfasserin aut Iffat Jahan verfasserin aut Zubair Mahmood Kamal verfasserin aut Humaira Hasin verfasserin aut Munzur-E-Murshid verfasserin aut Shamsun Nahar verfasserin aut Monami Haque verfasserin aut Siddhartha Dutta verfasserin aut Jha Pallavi Abhayanand verfasserin aut Rimple Jeet Kaur verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Renata Cristina Rezende Macedo do Nascimento verfasserin aut Isabella Piassi Dias Godói verfasserin aut Isabella Piassi Dias Godói verfasserin aut Mohammed Irfan verfasserin aut Adefolarin A. Amu verfasserin aut Patrick Matowa verfasserin aut Joseph Acolatse verfasserin aut Robert Incoom verfasserin aut Israel Abebrese Sefah verfasserin aut Israel Abebrese Sefah verfasserin aut Jitendra Acharya verfasserin aut Sylvia Opanga verfasserin aut Lisper Wangeci Njeri verfasserin aut David Kimonge verfasserin aut Hye-Young Kwon verfasserin aut SeungJin Bae verfasserin aut Karen Koh Pek Khuan verfasserin aut Abdullahi Rabiu Abubakar verfasserin aut Ibrahim Haruna Sani verfasserin aut Tanveer Ahmed Khan verfasserin aut Shahzad Hussain verfasserin aut Zikria Saleem verfasserin aut Oliver Ombeva Malande verfasserin aut Oliver Ombeva Malande verfasserin aut Thereza Piloya-Were verfasserin aut Rosana Gambogi verfasserin aut Carla Hernandez Ortiz verfasserin aut Luke Alutuli verfasserin aut Aubrey Chichonyi Kalungia verfasserin aut Iris Hoxha verfasserin aut Vanda Marković-Peković verfasserin aut Biljana Tubic verfasserin aut Biljana Tubic verfasserin aut Guenka Petrova verfasserin aut Konstantin Tachkov verfasserin aut Ott Laius verfasserin aut András Harsanyi verfasserin aut András Inotai verfasserin aut András Inotai verfasserin aut Arianit Jakupi verfasserin aut Svens Henkuzens verfasserin aut Kristina Garuoliene verfasserin aut Jolanta Gulbinovič verfasserin aut Magdalene Wladysiuk verfasserin aut Magdalene Wladysiuk verfasserin aut Jakub Rutkowski verfasserin aut Ileana Mardare verfasserin aut Jurij Fürst verfasserin aut Stuart McTaggart verfasserin aut Sean MacBride-Stewart verfasserin aut Caridad Pontes verfasserin aut Caridad Pontes verfasserin aut Corinne Zara verfasserin aut Eunice Twumwaa Tagoe verfasserin aut Rita Banzi verfasserin aut Janney Wale verfasserin aut Mihajlo Jakovljevic verfasserin aut Mihajlo Jakovljevic verfasserin aut In Frontiers in Public Health Frontiers Media S.A., 2013 9(2021) (DE-627)742224589 (DE-600)2711781-9 22962565 nnns volume:9 year:2021 https://doi.org/10.3389/fpubh.2021.671961 kostenfrei https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad kostenfrei https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full kostenfrei https://doaj.org/toc/2296-2565 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 |
allfields_unstemmed |
10.3389/fpubh.2021.671961 doi (DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad DE-627 ger DE-627 rakwb eng RA1-1270 Brian Godman verfasserin aut The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine Brian Godman verfasserin aut Brian Godman verfasserin aut Mainul Haque verfasserin aut Trudy Leong verfasserin aut Eleonora Allocati verfasserin aut Santosh Kumar verfasserin aut Salequl Islam verfasserin aut Jaykaran Charan verfasserin aut Farhana Akter verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Carlos Vassalo verfasserin aut Muhammed Abu Bakar verfasserin aut Sagir Abdur Rahim verfasserin aut Nusrat Sultana verfasserin aut Farzana Deeba verfasserin aut M. A. Halim Khan verfasserin aut A. B. M. Muksudul Alam verfasserin aut Iffat Jahan verfasserin aut Zubair Mahmood Kamal verfasserin aut Humaira Hasin verfasserin aut Munzur-E-Murshid verfasserin aut Shamsun Nahar verfasserin aut Monami Haque verfasserin aut Siddhartha Dutta verfasserin aut Jha Pallavi Abhayanand verfasserin aut Rimple Jeet Kaur verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Renata Cristina Rezende Macedo do Nascimento verfasserin aut Isabella Piassi Dias Godói verfasserin aut Isabella Piassi Dias Godói verfasserin aut Mohammed Irfan verfasserin aut Adefolarin A. Amu verfasserin aut Patrick Matowa verfasserin aut Joseph Acolatse verfasserin aut Robert Incoom verfasserin aut Israel Abebrese Sefah verfasserin aut Israel Abebrese Sefah verfasserin aut Jitendra Acharya verfasserin aut Sylvia Opanga verfasserin aut Lisper Wangeci Njeri verfasserin aut David Kimonge verfasserin aut Hye-Young Kwon verfasserin aut SeungJin Bae verfasserin aut Karen Koh Pek Khuan verfasserin aut Abdullahi Rabiu Abubakar verfasserin aut Ibrahim Haruna Sani verfasserin aut Tanveer Ahmed Khan verfasserin aut Shahzad Hussain verfasserin aut Zikria Saleem verfasserin aut Oliver Ombeva Malande verfasserin aut Oliver Ombeva Malande verfasserin aut Thereza Piloya-Were verfasserin aut Rosana Gambogi verfasserin aut Carla Hernandez Ortiz verfasserin aut Luke Alutuli verfasserin aut Aubrey Chichonyi Kalungia verfasserin aut Iris Hoxha verfasserin aut Vanda Marković-Peković verfasserin aut Biljana Tubic verfasserin aut Biljana Tubic verfasserin aut Guenka Petrova verfasserin aut Konstantin Tachkov verfasserin aut Ott Laius verfasserin aut András Harsanyi verfasserin aut András Inotai verfasserin aut András Inotai verfasserin aut Arianit Jakupi verfasserin aut Svens Henkuzens verfasserin aut Kristina Garuoliene verfasserin aut Jolanta Gulbinovič verfasserin aut Magdalene Wladysiuk verfasserin aut Magdalene Wladysiuk verfasserin aut Jakub Rutkowski verfasserin aut Ileana Mardare verfasserin aut Jurij Fürst verfasserin aut Stuart McTaggart verfasserin aut Sean MacBride-Stewart verfasserin aut Caridad Pontes verfasserin aut Caridad Pontes verfasserin aut Corinne Zara verfasserin aut Eunice Twumwaa Tagoe verfasserin aut Rita Banzi verfasserin aut Janney Wale verfasserin aut Mihajlo Jakovljevic verfasserin aut Mihajlo Jakovljevic verfasserin aut In Frontiers in Public Health Frontiers Media S.A., 2013 9(2021) (DE-627)742224589 (DE-600)2711781-9 22962565 nnns volume:9 year:2021 https://doi.org/10.3389/fpubh.2021.671961 kostenfrei https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad kostenfrei https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full kostenfrei https://doaj.org/toc/2296-2565 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 |
allfieldsGer |
10.3389/fpubh.2021.671961 doi (DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad DE-627 ger DE-627 rakwb eng RA1-1270 Brian Godman verfasserin aut The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine Brian Godman verfasserin aut Brian Godman verfasserin aut Mainul Haque verfasserin aut Trudy Leong verfasserin aut Eleonora Allocati verfasserin aut Santosh Kumar verfasserin aut Salequl Islam verfasserin aut Jaykaran Charan verfasserin aut Farhana Akter verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Carlos Vassalo verfasserin aut Muhammed Abu Bakar verfasserin aut Sagir Abdur Rahim verfasserin aut Nusrat Sultana verfasserin aut Farzana Deeba verfasserin aut M. A. Halim Khan verfasserin aut A. B. M. Muksudul Alam verfasserin aut Iffat Jahan verfasserin aut Zubair Mahmood Kamal verfasserin aut Humaira Hasin verfasserin aut Munzur-E-Murshid verfasserin aut Shamsun Nahar verfasserin aut Monami Haque verfasserin aut Siddhartha Dutta verfasserin aut Jha Pallavi Abhayanand verfasserin aut Rimple Jeet Kaur verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Renata Cristina Rezende Macedo do Nascimento verfasserin aut Isabella Piassi Dias Godói verfasserin aut Isabella Piassi Dias Godói verfasserin aut Mohammed Irfan verfasserin aut Adefolarin A. Amu verfasserin aut Patrick Matowa verfasserin aut Joseph Acolatse verfasserin aut Robert Incoom verfasserin aut Israel Abebrese Sefah verfasserin aut Israel Abebrese Sefah verfasserin aut Jitendra Acharya verfasserin aut Sylvia Opanga verfasserin aut Lisper Wangeci Njeri verfasserin aut David Kimonge verfasserin aut Hye-Young Kwon verfasserin aut SeungJin Bae verfasserin aut Karen Koh Pek Khuan verfasserin aut Abdullahi Rabiu Abubakar verfasserin aut Ibrahim Haruna Sani verfasserin aut Tanveer Ahmed Khan verfasserin aut Shahzad Hussain verfasserin aut Zikria Saleem verfasserin aut Oliver Ombeva Malande verfasserin aut Oliver Ombeva Malande verfasserin aut Thereza Piloya-Were verfasserin aut Rosana Gambogi verfasserin aut Carla Hernandez Ortiz verfasserin aut Luke Alutuli verfasserin aut Aubrey Chichonyi Kalungia verfasserin aut Iris Hoxha verfasserin aut Vanda Marković-Peković verfasserin aut Biljana Tubic verfasserin aut Biljana Tubic verfasserin aut Guenka Petrova verfasserin aut Konstantin Tachkov verfasserin aut Ott Laius verfasserin aut András Harsanyi verfasserin aut András Inotai verfasserin aut András Inotai verfasserin aut Arianit Jakupi verfasserin aut Svens Henkuzens verfasserin aut Kristina Garuoliene verfasserin aut Jolanta Gulbinovič verfasserin aut Magdalene Wladysiuk verfasserin aut Magdalene Wladysiuk verfasserin aut Jakub Rutkowski verfasserin aut Ileana Mardare verfasserin aut Jurij Fürst verfasserin aut Stuart McTaggart verfasserin aut Sean MacBride-Stewart verfasserin aut Caridad Pontes verfasserin aut Caridad Pontes verfasserin aut Corinne Zara verfasserin aut Eunice Twumwaa Tagoe verfasserin aut Rita Banzi verfasserin aut Janney Wale verfasserin aut Mihajlo Jakovljevic verfasserin aut Mihajlo Jakovljevic verfasserin aut In Frontiers in Public Health Frontiers Media S.A., 2013 9(2021) (DE-627)742224589 (DE-600)2711781-9 22962565 nnns volume:9 year:2021 https://doi.org/10.3389/fpubh.2021.671961 kostenfrei https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad kostenfrei https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full kostenfrei https://doaj.org/toc/2296-2565 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 |
allfieldsSound |
10.3389/fpubh.2021.671961 doi (DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad DE-627 ger DE-627 rakwb eng RA1-1270 Brian Godman verfasserin aut The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine Brian Godman verfasserin aut Brian Godman verfasserin aut Mainul Haque verfasserin aut Trudy Leong verfasserin aut Eleonora Allocati verfasserin aut Santosh Kumar verfasserin aut Salequl Islam verfasserin aut Jaykaran Charan verfasserin aut Farhana Akter verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Amanj Kurdi verfasserin aut Carlos Vassalo verfasserin aut Muhammed Abu Bakar verfasserin aut Sagir Abdur Rahim verfasserin aut Nusrat Sultana verfasserin aut Farzana Deeba verfasserin aut M. A. Halim Khan verfasserin aut A. B. M. Muksudul Alam verfasserin aut Iffat Jahan verfasserin aut Zubair Mahmood Kamal verfasserin aut Humaira Hasin verfasserin aut Munzur-E-Murshid verfasserin aut Shamsun Nahar verfasserin aut Monami Haque verfasserin aut Siddhartha Dutta verfasserin aut Jha Pallavi Abhayanand verfasserin aut Rimple Jeet Kaur verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Godfrey Mutashambara Rwegerera verfasserin aut Renata Cristina Rezende Macedo do Nascimento verfasserin aut Isabella Piassi Dias Godói verfasserin aut Isabella Piassi Dias Godói verfasserin aut Mohammed Irfan verfasserin aut Adefolarin A. Amu verfasserin aut Patrick Matowa verfasserin aut Joseph Acolatse verfasserin aut Robert Incoom verfasserin aut Israel Abebrese Sefah verfasserin aut Israel Abebrese Sefah verfasserin aut Jitendra Acharya verfasserin aut Sylvia Opanga verfasserin aut Lisper Wangeci Njeri verfasserin aut David Kimonge verfasserin aut Hye-Young Kwon verfasserin aut SeungJin Bae verfasserin aut Karen Koh Pek Khuan verfasserin aut Abdullahi Rabiu Abubakar verfasserin aut Ibrahim Haruna Sani verfasserin aut Tanveer Ahmed Khan verfasserin aut Shahzad Hussain verfasserin aut Zikria Saleem verfasserin aut Oliver Ombeva Malande verfasserin aut Oliver Ombeva Malande verfasserin aut Thereza Piloya-Were verfasserin aut Rosana Gambogi verfasserin aut Carla Hernandez Ortiz verfasserin aut Luke Alutuli verfasserin aut Aubrey Chichonyi Kalungia verfasserin aut Iris Hoxha verfasserin aut Vanda Marković-Peković verfasserin aut Biljana Tubic verfasserin aut Biljana Tubic verfasserin aut Guenka Petrova verfasserin aut Konstantin Tachkov verfasserin aut Ott Laius verfasserin aut András Harsanyi verfasserin aut András Inotai verfasserin aut András Inotai verfasserin aut Arianit Jakupi verfasserin aut Svens Henkuzens verfasserin aut Kristina Garuoliene verfasserin aut Jolanta Gulbinovič verfasserin aut Magdalene Wladysiuk verfasserin aut Magdalene Wladysiuk verfasserin aut Jakub Rutkowski verfasserin aut Ileana Mardare verfasserin aut Jurij Fürst verfasserin aut Stuart McTaggart verfasserin aut Sean MacBride-Stewart verfasserin aut Caridad Pontes verfasserin aut Caridad Pontes verfasserin aut Corinne Zara verfasserin aut Eunice Twumwaa Tagoe verfasserin aut Rita Banzi verfasserin aut Janney Wale verfasserin aut Mihajlo Jakovljevic verfasserin aut Mihajlo Jakovljevic verfasserin aut In Frontiers in Public Health Frontiers Media S.A., 2013 9(2021) (DE-627)742224589 (DE-600)2711781-9 22962565 nnns volume:9 year:2021 https://doi.org/10.3389/fpubh.2021.671961 kostenfrei https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad kostenfrei https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full kostenfrei https://doaj.org/toc/2296-2565 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 |
language |
English |
source |
In Frontiers in Public Health 9(2021) volume:9 year:2021 |
sourceStr |
In Frontiers in Public Health 9(2021) volume:9 year:2021 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Africa biosimilars cross-national study drug utilisation Europe health policy Public aspects of medicine |
isfreeaccess_bool |
true |
container_title |
Frontiers in Public Health |
authorswithroles_txt_mv |
Brian Godman @@aut@@ Mainul Haque @@aut@@ Trudy Leong @@aut@@ Eleonora Allocati @@aut@@ Santosh Kumar @@aut@@ Salequl Islam @@aut@@ Jaykaran Charan @@aut@@ Farhana Akter @@aut@@ Amanj Kurdi @@aut@@ Carlos Vassalo @@aut@@ Muhammed Abu Bakar @@aut@@ Sagir Abdur Rahim @@aut@@ Nusrat Sultana @@aut@@ Farzana Deeba @@aut@@ M. A. Halim Khan @@aut@@ A. B. M. Muksudul Alam @@aut@@ Iffat Jahan @@aut@@ Zubair Mahmood Kamal @@aut@@ Humaira Hasin @@aut@@ Munzur-E-Murshid @@aut@@ Shamsun Nahar @@aut@@ Monami Haque @@aut@@ Siddhartha Dutta @@aut@@ Jha Pallavi Abhayanand @@aut@@ Rimple Jeet Kaur @@aut@@ Godfrey Mutashambara Rwegerera @@aut@@ Renata Cristina Rezende Macedo do Nascimento @@aut@@ Isabella Piassi Dias Godói @@aut@@ Mohammed Irfan @@aut@@ Adefolarin A. Amu @@aut@@ Patrick Matowa @@aut@@ Joseph Acolatse @@aut@@ Robert Incoom @@aut@@ Israel Abebrese Sefah @@aut@@ Jitendra Acharya @@aut@@ Sylvia Opanga @@aut@@ Lisper Wangeci Njeri @@aut@@ David Kimonge @@aut@@ Hye-Young Kwon @@aut@@ SeungJin Bae @@aut@@ Karen Koh Pek Khuan @@aut@@ Abdullahi Rabiu Abubakar @@aut@@ Ibrahim Haruna Sani @@aut@@ Tanveer Ahmed Khan @@aut@@ Shahzad Hussain @@aut@@ Zikria Saleem @@aut@@ Oliver Ombeva Malande @@aut@@ Thereza Piloya-Were @@aut@@ Rosana Gambogi @@aut@@ Carla Hernandez Ortiz @@aut@@ Luke Alutuli @@aut@@ Aubrey Chichonyi Kalungia @@aut@@ Iris Hoxha @@aut@@ Vanda Marković-Peković @@aut@@ Biljana Tubic @@aut@@ Guenka Petrova @@aut@@ Konstantin Tachkov @@aut@@ Ott Laius @@aut@@ András Harsanyi @@aut@@ András Inotai @@aut@@ Arianit Jakupi @@aut@@ Svens Henkuzens @@aut@@ Kristina Garuoliene @@aut@@ Jolanta Gulbinovič @@aut@@ Magdalene Wladysiuk @@aut@@ Jakub Rutkowski @@aut@@ Ileana Mardare @@aut@@ Jurij Fürst @@aut@@ Stuart McTaggart @@aut@@ Sean MacBride-Stewart @@aut@@ Caridad Pontes @@aut@@ Corinne Zara @@aut@@ Eunice Twumwaa Tagoe @@aut@@ Rita Banzi @@aut@@ Janney Wale @@aut@@ Mihajlo Jakovljevic @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
742224589 |
id |
DOAJ062907832 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ062907832</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502115246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fpubh.2021.671961</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ062907832</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RA1-1270</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Africa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biosimilars</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cross-national study</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug utilisation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">health policy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Public aspects of medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mainul Haque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Leong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleonora Allocati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Santosh Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Salequl Islam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaykaran Charan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farhana Akter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Vassalo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhammed Abu Bakar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sagir Abdur Rahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nusrat Sultana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farzana Deeba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. A. Halim Khan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. B. M. Muksudul Alam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iffat Jahan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zubair Mahmood Kamal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Humaira Hasin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Munzur-E-Murshid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shamsun Nahar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Monami Haque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Siddhartha Dutta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jha Pallavi Abhayanand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rimple Jeet Kaur</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Godfrey Mutashambara Rwegerera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Godfrey Mutashambara Rwegerera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Renata Cristina Rezende Macedo do Nascimento</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabella Piassi Dias Godói</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabella Piassi Dias Godói</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohammed Irfan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adefolarin A. Amu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Matowa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph Acolatse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Incoom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Israel Abebrese Sefah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Israel Abebrese Sefah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jitendra Acharya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sylvia Opanga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lisper Wangeci Njeri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Kimonge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hye-Young Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SeungJin Bae</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karen Koh Pek Khuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abdullahi Rabiu Abubakar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ibrahim Haruna Sani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tanveer Ahmed Khan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shahzad Hussain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zikria Saleem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver Ombeva Malande</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver Ombeva Malande</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thereza Piloya-Were</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosana Gambogi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carla Hernandez Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luke Alutuli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aubrey Chichonyi Kalungia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iris Hoxha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vanda Marković-Peković</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biljana Tubic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biljana Tubic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guenka Petrova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantin Tachkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ott Laius</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Harsanyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Inotai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Inotai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Arianit Jakupi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Svens Henkuzens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kristina Garuoliene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolanta Gulbinovič</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magdalene Wladysiuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magdalene Wladysiuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jakub Rutkowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ileana Mardare</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jurij Fürst</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stuart McTaggart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sean MacBride-Stewart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caridad Pontes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caridad Pontes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Corinne Zara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Twumwaa Tagoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Banzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janney Wale</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mihajlo Jakovljevic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mihajlo Jakovljevic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Public Health</subfield><subfield code="d">Frontiers Media S.A., 2013</subfield><subfield code="g">9(2021)</subfield><subfield code="w">(DE-627)742224589</subfield><subfield code="w">(DE-600)2711781-9</subfield><subfield code="x">22962565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fpubh.2021.671961</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2296-2565</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Brian Godman |
spellingShingle |
Brian Godman misc RA1-1270 misc Africa misc biosimilars misc cross-national study misc drug utilisation misc Europe misc health policy misc Public aspects of medicine The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
authorStr |
Brian Godman |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)742224589 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RA1-1270 |
illustrated |
Not Illustrated |
issn |
22962565 |
topic_title |
RA1-1270 The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future Africa biosimilars cross-national study drug utilisation Europe health policy |
topic |
misc RA1-1270 misc Africa misc biosimilars misc cross-national study misc drug utilisation misc Europe misc health policy misc Public aspects of medicine |
topic_unstemmed |
misc RA1-1270 misc Africa misc biosimilars misc cross-national study misc drug utilisation misc Europe misc health policy misc Public aspects of medicine |
topic_browse |
misc RA1-1270 misc Africa misc biosimilars misc cross-national study misc drug utilisation misc Europe misc health policy misc Public aspects of medicine |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Frontiers in Public Health |
hierarchy_parent_id |
742224589 |
hierarchy_top_title |
Frontiers in Public Health |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)742224589 (DE-600)2711781-9 |
title |
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
ctrlnum |
(DE-627)DOAJ062907832 (DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad |
title_full |
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
author_sort |
Brian Godman |
journal |
Frontiers in Public Health |
journalStr |
Frontiers in Public Health |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
author_browse |
Brian Godman Mainul Haque Trudy Leong Eleonora Allocati Santosh Kumar Salequl Islam Jaykaran Charan Farhana Akter Amanj Kurdi Carlos Vassalo Muhammed Abu Bakar Sagir Abdur Rahim Nusrat Sultana Farzana Deeba M. A. Halim Khan A. B. M. Muksudul Alam Iffat Jahan Zubair Mahmood Kamal Humaira Hasin Munzur-E-Murshid Shamsun Nahar Monami Haque Siddhartha Dutta Jha Pallavi Abhayanand Rimple Jeet Kaur Godfrey Mutashambara Rwegerera Renata Cristina Rezende Macedo do Nascimento Isabella Piassi Dias Godói Mohammed Irfan Adefolarin A. Amu Patrick Matowa Joseph Acolatse Robert Incoom Israel Abebrese Sefah Jitendra Acharya Sylvia Opanga Lisper Wangeci Njeri David Kimonge Hye-Young Kwon SeungJin Bae Karen Koh Pek Khuan Abdullahi Rabiu Abubakar Ibrahim Haruna Sani Tanveer Ahmed Khan Shahzad Hussain Zikria Saleem Oliver Ombeva Malande Thereza Piloya-Were Rosana Gambogi Carla Hernandez Ortiz Luke Alutuli Aubrey Chichonyi Kalungia Iris Hoxha Vanda Marković-Peković Biljana Tubic Guenka Petrova Konstantin Tachkov Ott Laius András Harsanyi András Inotai Arianit Jakupi Svens Henkuzens Kristina Garuoliene Jolanta Gulbinovič Magdalene Wladysiuk Jakub Rutkowski Ileana Mardare Jurij Fürst Stuart McTaggart Sean MacBride-Stewart Caridad Pontes Corinne Zara Eunice Twumwaa Tagoe Rita Banzi Janney Wale Mihajlo Jakovljevic |
container_volume |
9 |
class |
RA1-1270 |
format_se |
Elektronische Aufsätze |
author-letter |
Brian Godman |
doi_str_mv |
10.3389/fpubh.2021.671961 |
author2-role |
verfasserin |
title_sort |
current situation regarding long-acting insulin analogues including biosimilars among african, asian, european, and south american countries; findings and implications for the future |
callnumber |
RA1-1270 |
title_auth |
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
abstract |
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. |
abstractGer |
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. |
abstract_unstemmed |
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future |
url |
https://doi.org/10.3389/fpubh.2021.671961 https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full https://doaj.org/toc/2296-2565 |
remote_bool |
true |
author2 |
Brian Godman Mainul Haque Trudy Leong Eleonora Allocati Santosh Kumar Salequl Islam Jaykaran Charan Farhana Akter Amanj Kurdi Carlos Vassalo Muhammed Abu Bakar Sagir Abdur Rahim Nusrat Sultana Farzana Deeba M. A. Halim Khan A. B. M. Muksudul Alam Iffat Jahan Zubair Mahmood Kamal Humaira Hasin Munzur-E-Murshid Shamsun Nahar Monami Haque Siddhartha Dutta Jha Pallavi Abhayanand Rimple Jeet Kaur Godfrey Mutashambara Rwegerera Renata Cristina Rezende Macedo do Nascimento Isabella Piassi Dias Godói Mohammed Irfan Adefolarin A. Amu Patrick Matowa Joseph Acolatse Robert Incoom Israel Abebrese Sefah Jitendra Acharya Sylvia Opanga Lisper Wangeci Njeri David Kimonge Hye-Young Kwon SeungJin Bae Karen Koh Pek Khuan Abdullahi Rabiu Abubakar Ibrahim Haruna Sani Tanveer Ahmed Khan Shahzad Hussain Zikria Saleem Oliver Ombeva Malande Thereza Piloya-Were Rosana Gambogi Carla Hernandez Ortiz Luke Alutuli Aubrey Chichonyi Kalungia Iris Hoxha Vanda Marković-Peković Biljana Tubic Guenka Petrova Konstantin Tachkov Ott Laius András Harsanyi András Inotai Arianit Jakupi Svens Henkuzens Kristina Garuoliene Jolanta Gulbinovič Magdalene Wladysiuk Jakub Rutkowski Ileana Mardare Jurij Fürst Stuart McTaggart Sean MacBride-Stewart Caridad Pontes Corinne Zara Eunice Twumwaa Tagoe Rita Banzi Janney Wale Mihajlo Jakovljevic |
author2Str |
Brian Godman Mainul Haque Trudy Leong Eleonora Allocati Santosh Kumar Salequl Islam Jaykaran Charan Farhana Akter Amanj Kurdi Carlos Vassalo Muhammed Abu Bakar Sagir Abdur Rahim Nusrat Sultana Farzana Deeba M. A. Halim Khan A. B. M. Muksudul Alam Iffat Jahan Zubair Mahmood Kamal Humaira Hasin Munzur-E-Murshid Shamsun Nahar Monami Haque Siddhartha Dutta Jha Pallavi Abhayanand Rimple Jeet Kaur Godfrey Mutashambara Rwegerera Renata Cristina Rezende Macedo do Nascimento Isabella Piassi Dias Godói Mohammed Irfan Adefolarin A. Amu Patrick Matowa Joseph Acolatse Robert Incoom Israel Abebrese Sefah Jitendra Acharya Sylvia Opanga Lisper Wangeci Njeri David Kimonge Hye-Young Kwon SeungJin Bae Karen Koh Pek Khuan Abdullahi Rabiu Abubakar Ibrahim Haruna Sani Tanveer Ahmed Khan Shahzad Hussain Zikria Saleem Oliver Ombeva Malande Thereza Piloya-Were Rosana Gambogi Carla Hernandez Ortiz Luke Alutuli Aubrey Chichonyi Kalungia Iris Hoxha Vanda Marković-Peković Biljana Tubic Guenka Petrova Konstantin Tachkov Ott Laius András Harsanyi András Inotai Arianit Jakupi Svens Henkuzens Kristina Garuoliene Jolanta Gulbinovič Magdalene Wladysiuk Jakub Rutkowski Ileana Mardare Jurij Fürst Stuart McTaggart Sean MacBride-Stewart Caridad Pontes Corinne Zara Eunice Twumwaa Tagoe Rita Banzi Janney Wale Mihajlo Jakovljevic |
ppnlink |
742224589 |
callnumber-subject |
RA - Public Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3389/fpubh.2021.671961 |
callnumber-a |
RA1-1270 |
up_date |
2024-07-03T14:44:45.866Z |
_version_ |
1803569474696118272 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ062907832</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502115246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fpubh.2021.671961</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ062907832</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ21e165a45cc44a40aaaa93c7005bfdad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RA1-1270</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Africa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biosimilars</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cross-national study</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug utilisation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">health policy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Public aspects of medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian Godman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mainul Haque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Trudy Leong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleonora Allocati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Santosh Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Salequl Islam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaykaran Charan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farhana Akter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amanj Kurdi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Vassalo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Muhammed Abu Bakar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sagir Abdur Rahim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nusrat Sultana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farzana Deeba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. A. Halim Khan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. B. M. Muksudul Alam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iffat Jahan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zubair Mahmood Kamal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Humaira Hasin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Munzur-E-Murshid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shamsun Nahar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Monami Haque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Siddhartha Dutta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jha Pallavi Abhayanand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rimple Jeet Kaur</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Godfrey Mutashambara Rwegerera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Godfrey Mutashambara Rwegerera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Renata Cristina Rezende Macedo do Nascimento</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabella Piassi Dias Godói</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isabella Piassi Dias Godói</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohammed Irfan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adefolarin A. Amu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrick Matowa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph Acolatse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Incoom</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Israel Abebrese Sefah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Israel Abebrese Sefah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jitendra Acharya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sylvia Opanga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lisper Wangeci Njeri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Kimonge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hye-Young Kwon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SeungJin Bae</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karen Koh Pek Khuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Abdullahi Rabiu Abubakar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ibrahim Haruna Sani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tanveer Ahmed Khan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shahzad Hussain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zikria Saleem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver Ombeva Malande</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oliver Ombeva Malande</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thereza Piloya-Were</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosana Gambogi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carla Hernandez Ortiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luke Alutuli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Aubrey Chichonyi Kalungia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Iris Hoxha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vanda Marković-Peković</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biljana Tubic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Biljana Tubic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guenka Petrova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Konstantin Tachkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ott Laius</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Harsanyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Inotai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">András Inotai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Arianit Jakupi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Svens Henkuzens</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kristina Garuoliene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jolanta Gulbinovič</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magdalene Wladysiuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magdalene Wladysiuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jakub Rutkowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ileana Mardare</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jurij Fürst</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stuart McTaggart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sean MacBride-Stewart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caridad Pontes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Caridad Pontes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Corinne Zara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eunice Twumwaa Tagoe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rita Banzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janney Wale</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mihajlo Jakovljevic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mihajlo Jakovljevic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Public Health</subfield><subfield code="d">Frontiers Media S.A., 2013</subfield><subfield code="g">9(2021)</subfield><subfield code="w">(DE-627)742224589</subfield><subfield code="w">(DE-600)2711781-9</subfield><subfield code="x">22962565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fpubh.2021.671961</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/21e165a45cc44a40aaaa93c7005bfdad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.frontiersin.org/articles/10.3389/fpubh.2021.671961/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2296-2565</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield></datafield></record></collection>
|
score |
7.39927 |